Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase

Giuseppe S A Longo, Julie Izzo, Richard Gorlick, Debabrata Banerjee, Suresh C. Jhanwar, Joseph R. Bertino

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Four new cell lines were established from the primary tumors of patients with untreated colorectal adenocarcinoma. Drug sensitivity and characterization of these cell lines was performed. Three of the four cell lines formed colonies in soft agar and all were tumorigenic in nude mice. The cell lines were morphologically similar but had differences in growth characteristics. Two of the cell lines, C18 (CCCL-4) and C29 (CCCL-6), had a longer doubling time compared with C85 (CCCL-1) and C86 (CCCL-2). The C18 and C29 cell lines had chromosome 17 abnormalities and evidence by immunohistochemistry of a mutant p53 and had decreased levels of thymidylate synthase and dihydrofolate reductase proteins, associated with decreased thymidylate synthase catalytic activity in C18 and no detectable activity in C29. Raltitrexed and GW1843U89 showed potent cytotoxic activity and all four cell lines displayed similar cytotoxicity to these folate thymidylate synthase inhibitors. The C18 and C29 cell lines were in general resistant to the other agents tested (methotrexate, 5-fluorouracil, nolatrexed) when compared with the C85 and C86 cell lines. These new cell lines may be useful for the study of colorectal adenocarcinoma and for evaluating new drugs or treatment schedules.

Original languageEnglish (US)
Pages (from-to)309-314
Number of pages6
JournalOncology Research
Volume12
Issue number8
StatePublished - 2000
Externally publishedYes

Fingerprint

Folic Acid Antagonists
Thymidylate Synthase
Colon
Adenocarcinoma
Cell Line
Pharmaceutical Preparations
Chromosomes, Human, Pair 17
Folic Acid
Nude Mice
Methotrexate
Chromosome Aberrations
Fluorouracil
Agar
Appointments and Schedules
Immunohistochemistry

Keywords

  • Adenocarcinoma
  • Antifolate
  • Colorectal
  • Thymidylale synthase

ASJC Scopus subject areas

  • Cancer Research

Cite this

Longo, G. S. A., Izzo, J., Gorlick, R., Banerjee, D., Jhanwar, S. C., & Bertino, J. R. (2000). Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. Oncology Research, 12(8), 309-314.

Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. / Longo, Giuseppe S A; Izzo, Julie; Gorlick, Richard; Banerjee, Debabrata; Jhanwar, Suresh C.; Bertino, Joseph R.

In: Oncology Research, Vol. 12, No. 8, 2000, p. 309-314.

Research output: Contribution to journalArticle

Longo, GSA, Izzo, J, Gorlick, R, Banerjee, D, Jhanwar, SC & Bertino, JR 2000, 'Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase', Oncology Research, vol. 12, no. 8, pp. 309-314.
Longo, Giuseppe S A ; Izzo, Julie ; Gorlick, Richard ; Banerjee, Debabrata ; Jhanwar, Suresh C. ; Bertino, Joseph R. / Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. In: Oncology Research. 2000 ; Vol. 12, No. 8. pp. 309-314.
@article{ef5c90e264bc4561b94f1fe03dd1bd12,
title = "Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase",
abstract = "Four new cell lines were established from the primary tumors of patients with untreated colorectal adenocarcinoma. Drug sensitivity and characterization of these cell lines was performed. Three of the four cell lines formed colonies in soft agar and all were tumorigenic in nude mice. The cell lines were morphologically similar but had differences in growth characteristics. Two of the cell lines, C18 (CCCL-4) and C29 (CCCL-6), had a longer doubling time compared with C85 (CCCL-1) and C86 (CCCL-2). The C18 and C29 cell lines had chromosome 17 abnormalities and evidence by immunohistochemistry of a mutant p53 and had decreased levels of thymidylate synthase and dihydrofolate reductase proteins, associated with decreased thymidylate synthase catalytic activity in C18 and no detectable activity in C29. Raltitrexed and GW1843U89 showed potent cytotoxic activity and all four cell lines displayed similar cytotoxicity to these folate thymidylate synthase inhibitors. The C18 and C29 cell lines were in general resistant to the other agents tested (methotrexate, 5-fluorouracil, nolatrexed) when compared with the C85 and C86 cell lines. These new cell lines may be useful for the study of colorectal adenocarcinoma and for evaluating new drugs or treatment schedules.",
keywords = "Adenocarcinoma, Antifolate, Colorectal, Thymidylale synthase",
author = "Longo, {Giuseppe S A} and Julie Izzo and Richard Gorlick and Debabrata Banerjee and Jhanwar, {Suresh C.} and Bertino, {Joseph R.}",
year = "2000",
language = "English (US)",
volume = "12",
pages = "309--314",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "8",

}

TY - JOUR

T1 - Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase

AU - Longo, Giuseppe S A

AU - Izzo, Julie

AU - Gorlick, Richard

AU - Banerjee, Debabrata

AU - Jhanwar, Suresh C.

AU - Bertino, Joseph R.

PY - 2000

Y1 - 2000

N2 - Four new cell lines were established from the primary tumors of patients with untreated colorectal adenocarcinoma. Drug sensitivity and characterization of these cell lines was performed. Three of the four cell lines formed colonies in soft agar and all were tumorigenic in nude mice. The cell lines were morphologically similar but had differences in growth characteristics. Two of the cell lines, C18 (CCCL-4) and C29 (CCCL-6), had a longer doubling time compared with C85 (CCCL-1) and C86 (CCCL-2). The C18 and C29 cell lines had chromosome 17 abnormalities and evidence by immunohistochemistry of a mutant p53 and had decreased levels of thymidylate synthase and dihydrofolate reductase proteins, associated with decreased thymidylate synthase catalytic activity in C18 and no detectable activity in C29. Raltitrexed and GW1843U89 showed potent cytotoxic activity and all four cell lines displayed similar cytotoxicity to these folate thymidylate synthase inhibitors. The C18 and C29 cell lines were in general resistant to the other agents tested (methotrexate, 5-fluorouracil, nolatrexed) when compared with the C85 and C86 cell lines. These new cell lines may be useful for the study of colorectal adenocarcinoma and for evaluating new drugs or treatment schedules.

AB - Four new cell lines were established from the primary tumors of patients with untreated colorectal adenocarcinoma. Drug sensitivity and characterization of these cell lines was performed. Three of the four cell lines formed colonies in soft agar and all were tumorigenic in nude mice. The cell lines were morphologically similar but had differences in growth characteristics. Two of the cell lines, C18 (CCCL-4) and C29 (CCCL-6), had a longer doubling time compared with C85 (CCCL-1) and C86 (CCCL-2). The C18 and C29 cell lines had chromosome 17 abnormalities and evidence by immunohistochemistry of a mutant p53 and had decreased levels of thymidylate synthase and dihydrofolate reductase proteins, associated with decreased thymidylate synthase catalytic activity in C18 and no detectable activity in C29. Raltitrexed and GW1843U89 showed potent cytotoxic activity and all four cell lines displayed similar cytotoxicity to these folate thymidylate synthase inhibitors. The C18 and C29 cell lines were in general resistant to the other agents tested (methotrexate, 5-fluorouracil, nolatrexed) when compared with the C85 and C86 cell lines. These new cell lines may be useful for the study of colorectal adenocarcinoma and for evaluating new drugs or treatment schedules.

KW - Adenocarcinoma

KW - Antifolate

KW - Colorectal

KW - Thymidylale synthase

UR - http://www.scopus.com/inward/record.url?scp=0034578430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034578430&partnerID=8YFLogxK

M3 - Article

C2 - 11589301

AN - SCOPUS:0034578430

VL - 12

SP - 309

EP - 314

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 8

ER -